Company news

MiNK Therapeutics, Inc. news in 2025

MiNK Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

November 20, 2025

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

November 14, 2025

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

November 7, 2025

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

November 5, 2025

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

October 30, 2025

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

September 29, 2025

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

September 25, 2025

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

September 18, 2025

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

August 14, 2025

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

July 31, 2025

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

July 15, 2025

MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer

July 11, 2025

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

June 10, 2025

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

June 2, 2025

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

May 15, 2025

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

March 18, 2025

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

March 4, 2025

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

February 24, 2025

MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements

February 20, 2025

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

February 11, 2025

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

January 22, 2025

Calls in 2025

Decks in 2025